Table 2.
Control group | Model group | Aspirin group | DZD-H group | DZD-M group | DZD-L group | |
---|---|---|---|---|---|---|
MGS | 1.367 ± 1.245 | 5.633 ± 1.847a | 3.167 ± 1.315a,b | 2.033 ± 1.098b,c | 1.667 ± 1.093b,c | 2.900 ± 1.242a,b,d,e |
Blood flow of internal genital tract | ||||||
PSV of ovarian artery | 58.288 ± 11.853 | 45.772 ± 10.880a | 55.219 ± 15.668b | 60.400 ± 16.312b | 58.326 ± 9.813b | 46.538 ± 6.393a,c,d,e |
PSV of internal iliac artery | 51.176 ± 7.778 | 44.685 ± 9.038a | 51.516 ± 12.975b | 59.286 ± 14.137a,b,c | 51.431 ± 10.211b,d | 44.069 ± 8.650a,c,d,e |
Microvascular perfusion of pelvic wall | 53.783 ± 7.454 | 31.596 ± 7.682a | 60.992 ± 11.219b | 70.380 ± 15.757a,b,c | 56.901 ± 9.801b,d | 37.735 ± 6.219a,c,d,e |
Mesenteric blood flow perfusion | 90.596 ± 13.594 | 61.029 ± 21.219a | 91.209 ± 22.603b | 107.375 ± 22.902a,b,c | 85.818 ± 17.079b,d | 58.926 ± 15.59a,c,d,e |
a P < 0.05 compared with the control group; b P < 0.05 compared with the model group; c P < 0.05 compared with the aspirin group; d P < 0.05 compared with the DZD-H group; e P < 0.05 compared with the DZD-M group.